Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Prostate cancer updates at ASCO 2021

Neal Shore • 28 May 2021
ASCO 2021
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617

Neal Shore, FACS, MD, Carolina Urologic Research Center, Myrtle Beach, SC, shares presentations he is looking forward to at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, including data from the Phase III VISION trial (NCT03511664) of 177Lu-PSMA-617, a targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Dr Shore additionally mentions genomic profiling, PARP inhibitors, and gene mutation selective therapies as important topics in prostate cancer. This interview took place at the ASCO 2021 Virtual Meeting.

More from Neal Shore

0:56
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
Neal Shore • 26 Jan 2024
0:51
OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS
Neal Shore • 26 Jan 2024
0:44
PROpel: gene-by-gene efficacy of olaparib and abiraterone in mCRPC
Neal Shore • 26 Jan 2024
0:39
TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPC
Neal Shore • 26 Jan 2024

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals